The company's ADCs are based on pyrrolobenzodiazepine dimer technology, which is more effective in killing cancer cells than other ADCs. Their product candidates include ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701, and ADCT-212. ADC Therapeutics is committed to improving outcomes for patients with difficult-to-treat hematological cancers and solid tumors, with operations in Switzerland, the UK, the US, and a highly skilled global team.